India Lung Cancer Drugs Market Analysis

India Lung Cancer Drugs Market Analysis


$ 3999

The India Lung Cancer Drug Market is projected to grow from $174 Mn in 2022 to $409 Mn by 2030, registering a CAGR of 11.30% during the forecast period of 2022 - 2030. Lung cancer is the second most common cancer in India and is expected to become the most common cancer in the country by 2025. The India lung cancer drug market is dominated by a few large players, including Pfizer, AstraZeneca, and Roche.

ID: IN10INPH015 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Shivam Zalke

Buy Now

India Lung Cancer Drug Market Executive Summary

The India Lung Cancer Drug Market is projected to grow from $174 Mn in 2022 to $409 Mn by 2030, registering a CAGR of 11.30% during the forecast period of 2022 - 2030.

The India lung cancer drug market is a relatively small but growing industry. The increasing prevalence of lung cancer in India is one of the main drivers of the market. Lung cancer is the second most common cancer in India and is expected to become the most common cancer in the country by 2025.

The India lung cancer drug market is relatively small compared to the global market, but it is expected to grow in the coming years due to increasing healthcare expenditure, improving healthcare infrastructure, and the introduction of new, innovative drugs.

The India lung cancer drug market is dominated by a few large players, including Pfizer, AstraZeneca, and Roche. These companies have a strong presence in the market and offer a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies.

The Indian government also plays a significant role in the lung cancer drug market through its national health insurance program, which covers the costs of drugs for patients with lung cancer.

Overall, the India lung cancer drug market is expected to continue growing in the coming years, driven by the increasing incidence of lung cancer, advances in technology, and government support for research and development.

india lung cancer drugs market analysis

Market Dynamics

Market Drivers

The India lung cancer drug market is driven by several key factors, including:

  1. Increasing incidence of lung cancer: Lung cancer is the second most common cancer in India and is expected to become the most common cancer in the country by 2025
  2. Government support: The Indian government has taken steps to increase funding and support for cancer research, which is expected to drive innovation and the introduction of new drugs
  3. Advances in technology: The development of new, targeted therapies and immunotherapies for lung cancer has led to improved treatment outcomes and increased survival rates
  4. Growing aging population: As the population ages, the number of people with lung cancer will increase as lung cancer is more common in older adults
  5. Personalized medicine: The use of personalized medicine, which tailors treatment to the specific characteristics of a patient's cancer, is also driving growth in the lung cancer drug market in India
  6. Reimbursement policies: The Indian government's national health insurance program covers the costs of drugs for patients with lung cancer, which makes it more accessible for patients who are in need of them
  7. Increasing healthcare expenditure: The Indian government's increasing healthcare expenditure is also playing a major role in the growth of the lung cancer drug market
  8. Improving healthcare infrastructure: The Indian government's efforts to improve healthcare infrastructure are also facilitating market growth by providing better facilities and treatments to patients
  9. Growing awareness about cancer and its treatment: The increasing awareness about cancer and its treatment among the population is also driving the growth of the lung cancer drug market in India

Competitive Landscape

Key Players

The India lung cancer drug market is dominated by several key players, including:

  • Pfizer: Pfizer is a global pharmaceutical company that offers a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies
  • AstraZeneca: AstraZeneca is a British-Swedish multinational pharmaceutical and biopharmaceutical company that offers a range of drugs for the treatment of lung cancer, including targeted therapies
  • Roche: Roche is a Swiss multinational healthcare company that offers a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies
  • Merck: Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company that offers a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies
  • Novartis: Novartis is a Swiss multinational pharmaceutical company that offers a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies
  • Bristol-Myers Squibb: Bristol-Myers Squibb is an American multinational pharmaceutical company that offers a range of drugs for the treatment of lung cancer, including targeted therapies and immunotherapies

Indian companies: There are also several Indian pharmaceutical companies that have a presence in the lung cancer drug market in India, such as Cipla, Sun Pharmaceuticals, Dr. Reddy's Laboratories, etc.

These companies have a strong presence in the Indian lung cancer drug market and are likely to continue to dominate the market in the future.

Healthcare Policies and Regulatory Landscape

The Indian healthcare system is a mix of public and private healthcare, and it is regulated by the Ministry of Health and Family Welfare, the Central Drugs Standard Control Organization (CDSCO) and the state-level drugs control departments. The healthcare policies and regulatory landscape for the India lung cancer drug market are designed to ensure the safety and efficacy of drugs, as well as to ensure that drugs are accessible and affordable for patients.

The CDSCO is responsible for regulating the safety and efficacy of drugs, including those for the treatment of lung cancer. It reviews and approves drugs for sale in India, and also monitors their safety after they have been approved.

The Indian government also provides funding and support for research and development in the lung cancer drug market through organizations such as the Department of Biotechnology (DBT) and the Indian Council of Medical Research (ICMR).

The Indian government also plays a significant role in the lung cancer drug market through its national health insurance program, which covers the costs of drugs for patients with lung cancer. The reimbursement policies for cancer drugs are supportive of the market as it provides coverage for the drugs to patients who are in need of them.

Overall, the healthcare policies and regulatory landscape in India support the development and availability of new, innovative drugs for the treatment of lung cancer, while also ensuring that patients have access to safe and effective treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Drugs Market Segmentation

By Disease type

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)

By Drug

  • Gemzar
  • Paraplatin
  • Texotere
  • Others

By End-user

  • Hospitals
  • Clinics
  • Others

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 27 January 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up